Dasatinib Monohydrate: Potent Multitargeted Tyrosine Kinase Inhibitor for CML Research

Executive Summary: Dasatinib Monohydrate (BMS-354825) is a multitargeted tyrosine kinase inhibitor, exhibiting sub-nanomolar IC₅₀ for Src (0.55 nM) and low-nanomolar IC₅₀ for Bcr-Abl (3.0 nM) under standard in vitro assay conditions (ApexBio). It is effective against both nonmutated and imatinib-resistant BCR-ABL isoforms, supporting drug resistance research in chronic myeloid leukemia (CML) (Telerman et al., 2022). Dasatinib Monohydrate demonstrates broad-spectrum antiproliferative effects in hematological and solid tumor cell lines. In vivo, it reduces disease progression and bioluminescent signals in BCR-ABL mouse models. Approved by the FDA since 2006, it is standard in CML and Ph-positive ALL studies.

Biological Rationale

Chronic myeloid leukemia (CML) is driven by the BCR-ABL1 fusion gene, resulting from the Philadelphia (Ph) chromosome translocation. This fusion protein constitutively activates ABL tyrosine kinase, causing uncontrolled cell proliferation (Telerman et al., 2022). Tyrosine kinase inhibitors (TKIs) revolutionized CML therapy by selectively targeting BCR-ABL signaling. Dasatinib Monohydrate, a second-generation multitargeted TKI, was developed to overcome resistance to first-generation inhibitors (notably imatinib) and to inhibit a broader range of kinases implicated in tumor progression and microenvironmental signaling (ApexBio). This broad kinase inhibition profile allows for effective suppression of both canonical oncogenic drivers and compensatory pathways.

Mechanism of Action of Dasatinib Monohydrate

Dasatinib Monohydrate inhibits multiple tyrosine kinases via ATP-competitive binding. It targets ABL, SRC-family kinases (Src, Lck, Yes, Fyn), KIT, PDGFR, and others. The compound binds to the active conformation of the ABL kinase domain, blocking downstream phosphorylation events and cell proliferation. Its efficacy extends to BCR-ABL isoforms harboring common imatinib-resistant mutations (except T315I). Dasatinib also suppresses SRC-family kinases, which are involved in cellular adhesion, migration, and microenvironmental interactions. Thus, Dasatinib Monohydrate disrupts both leukemic cell-autonomous signaling and tumor-stromal crosstalk, relevant in both hematological and solid tumor models (Telerman et al., 2022).

Evidence & Benchmarks

• Dasatinib Monohydrate exhibits an IC₅₀ of 0.55 nM for Src and 3.0 nM for Bcr-Abl in enzyme inhibition assays at standard conditions (25°C, pH 7.5) (ApexBio).
• In vitro, Dasatinib Monohydrate inhibits proliferation of BCR-ABL+ cell lines and solid tumor cells at sub-micromolar concentrations (ApexBio).
• Dasatinib is active against imatinib-resistant BCR-ABL mutants except T315I (mutation panel, Table 1 in Telerman et al., 2022).
• In vivo, Dasatinib reduces leukemic burden and bioluminescent activity in BCR-ABL transgenic mouse models after daily oral dosing (2.5–10 mg/kg, 14 days) (Telerman et al., 2022).
• Dasatinib Monohydrate is clinically approved for CML and Ph-positive ALL (FDA, 2006; ApexBio).
• Neutrophil extracellular traps (NETs) are increased in CML, and TKI treatment modulates NET formation, with differential effects observed for distinct TKIs (Telerman et al., 2022, Figure 1/2).

Applications, Limits & Misconceptions

Dasatinib Monohydrate is widely used in CML research to interrogate kinase signaling, drug resistance, and tumor-microenvironment interactions. Its multitarget profile enables modeling of both on-target and off-target effects, making it suitable for both cell line and in vivo studies. The compound is also valuable for exploring kinase pathway crosstalk in solid tumors and assembloid systems. Notably, "Dasatinib Monohydrate: Advanced Mechanisms and Experiment..." focuses on experimental designs for BCR-ABL and SRC inhibition, while this article extends to clinical benchmarks and resistance data. For detailed workflow strategies, see "Dasatinib Monohydrate: Applied Workflows in CML and Kinas...", which outlines troubleshooting and advanced application; this article provides updated resistance profiles and in vivo efficacy data.

Common Pitfalls or Misconceptions

• Dasatinib does not inhibit all BCR-ABL mutants: The T315I mutation remains resistant (Telerman et al., 2022).
• Solubility limitations: The compound is insoluble in water and ethanol; use only DMSO (≥25.3 mg/mL) for stock solutions (ApexBio).
• Short-term solution stability: Stock solutions should be freshly prepared and stored at -20°C; avoid repeated freeze-thaw cycles.
• Not suitable for all solid tumor models: Efficacy is context- and pathway-dependent; validate in each system.
• Clinical cardiovascular risks: Some TKIs, including dasatinib, are associated with vascular events in patients (Telerman et al., 2022).

Workflow Integration & Parameters

Preparation: Dissolve Dasatinib Monohydrate in DMSO to prepare ≥25.3 mg/mL stock solutions. Store at -20°C. Use within one month to maintain potency. For cell-based assays, dilute into culture medium at final DMSO concentrations ≤0.1% v/v.

Concentrations: In vitro, effective concentrations typically range from 1 nM to 1 μM depending on cell type and endpoint. In vivo, preclinical studies use dosing regimens of 2.5–10 mg/kg/day orally in mouse models.

Controls: Always include vehicle (DMSO) and, where relevant, imatinib or other TKIs as comparative controls to assess specificity and resistance mechanisms.

For advanced microenvironment and resistance studies, see "Dasatinib Monohydrate: Unraveling Kinase Inhibition in Tu...", which uniquely addresses tumor-stromal interplay—this article integrates updated in vivo benchmarks and clinical context.

Conclusion & Outlook

Dasatinib Monohydrate (BMS-354825) is a cornerstone multitargeted tyrosine kinase inhibitor for CML, Ph-positive ALL, and advanced kinase pathway research. Its broad inhibitory profile, robust preclinical and clinical benchmarks, and validated use in resistance modeling underpin its utility. When used with attention to solubility, stability, and model-specific limitations, it enables high-confidence interrogation of kinase signaling and drug resistance mechanisms. For detailed product parameters and ordering, visit the official Dasatinib Monohydrate (B5954) page.